市場調查報告書
商品編碼
970252

羥氯喹市場成長機會、成長預測 (2020-2027年): 各產品類型、通路、疾病、地區

Hydroxychloroquine Market by Product type, Distribution Channel, and Disease : Global Opportunity Analysis and Industry Forecast, 2020-2027

出版日期: | 出版商: Allied Market Research | 英文 246 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球羥氯喹的市場規模在預測期間內預計以7.9%的年複合成長率發展,從2019年的19億美元,成長到2027年46億美元的規模。羥氯喹與氯喹組合有對新型冠狀病毒 (COVID-19) 的抗病毒活性的假設,美國和印度等,部分國家批准用作COVID-19的預防措施。

本報告提供全球羥氯喹的市場調查,市場定義和概要,價值鏈,COVID-19以及其他的市場影響因素分析,專利趨勢,市場規模的變化、預測,產品類型、通路、疾病、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等資訊彙整。

第1章 簡介

第2章 摘要整理

第3章 市場形勢

  • 市場定義、調查範圍
  • 主要調查結果
  • 專利分析
  • 價值鏈分析
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
    • COVID-19的影響

第4章 市場分析、預測:各產品類型

  • 概要
  • 平板電腦
  • API (醫藥品有效成分)
    • 主要趨勢、成長要素、市場機會
    • 市場規模、預測:各地區

第5章 市場分析、預測:各銷售管道

  • 概要
  • 院內藥局
  • 零售藥局
  • 線上藥局
  • 專門藥妝店
    • 主要趨勢、成長要素、市場機會
    • 市場規模、預測:各地區

第6章 市場分析、預測:各疾病

  • 概要
  • 瘧疾
  • 類風濕性關節炎
  • 紅斑
  • 冠狀病毒
  • 其他
    • 主要趨勢、成長要素、市場機會
    • 市場規模、預測:各地區

第7章 市場分析、預測:各地區、主要國家

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美、中東、非洲
    • 主要趨勢、成長要素、市場機會
    • 市場規模、預測:各產品類型
    • 市場規模、預測:各銷售管道
    • 市場規模、預測:各疾病種類
    • 市場規模、預測:各國

第8章 企業簡介

  • Cadila Healthcare Limited
  • Hikma Pharmaceuticals PLC
  • IPCA Laboratories Ltd.
  • Mylan N.V.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Taj Pharma Group
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited
目錄
Product Code: A07137

The global hydroxychloroquine market size was valued at $1.9 billion in 2019, and is anticipated to generate $4.6 billion by 2027. The market is projected to experience growth at a CAGR of 7.9% from 2020 to 2027.

Hydroxychloroquine, and anti-malarial drug, when combined with chloroquine has the potential to be the major game-changer in the medical history. In certain small and vitro, uncontrolled or poorly controlled clinical studies, it demonstrated antiviral activity against (SARS-CoV-2) severe acute respiratory syndrome-coronavirus-2. Such researches are considered as hypothesis. However, followed by the tweet of President Trump, it completely changed the scenario of the market, with reports of shortages of the medicine in pharmacies within 24 hours. Amidst the outbreak, certain nations such as the U.S. and India are endorsing its use as preventive measures for COVID-19.

The growth of the global hydroxychloroquine market is drive by surge in demand for the medication, which led to hike in production of the drug by the Indian Government. IPCA Laboratories, which have approximately 70% of the market share in this sector in India, has increased its production tenfold. However, the nationwide lockdown acted as a hindrance for growth of the global market. In addition, disruption in logistic chains and less availability of raw materials, which are mostly scoured from China have restrained the market growth. With the initiation of normal operation in China after the lockdown and backward integration of some industry players have helped the market to cope up to a certain extent.

In April 2019, IPCA Laboratories signed a contract to acquire Maharashtra-based Ramdev Chemical Pvt. Ltd. According to the contract, IPCA Laboratories is supposed to buy the company, which is associated with the marketing and manufacturing of advanced drug intermediates, active pharmaceutical ingredients (APIs), custom synthesis molecules, and fine chemicals. Thus, this initiative by IPCA Laboratories will help the company in increasing the production capacity of the drug and contribute in meeting the present demand.

On March 25 2020, the Indian Government imposed a ban on export of the drug to ensure that the nation had adequate stock of the medication to meet domestic needs. However, later the government decided to lift the ban partially. The SAARC nations along with other 30 nations and the U.S. and West Asia proposed India to lift the ban on export. Considering the high demand for the medication, pharmaceutical companies in the nation have planned to increase the production by 5 to 6 times to over 70 metric tons by May 2020. Apart from IPCA Laboratories Ltd., Zydus Cadila and Wallace Pharmaceuticals are some of the other leading manufacturers of hydroxychloroquine.

The global hydroxychloroquine market is segmented into product type, distribution channel, disease, and region. On the basis of product type, the market is bifurcated into tablet and active pharmaceutical ingredients. Depending on distribution channel, the market is fragmented into hospital pharmacy, online pharmacy, specialty drug store, and retail pharmacy. The diseases covered in the study include malaria, rheumatoid arthritis, lupus erythematosus, coronavirus, and others. Region wise, the hydroxychloroquine market analysis is done across North America, Europe, Asia-Pacific, and LAMEA (Latin America, Middle East, and Africa).

The key players operating in the hydroxychloroquine market are Cadila Healthcare Ltd., Hikma Pharmaceuticals PLC, Ipca Laboratories Ltd., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Taj Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Cadila. The companies have focused on various strategies such as new product launches, partnerships, acquisitions, and mergers for retaining their existing customer base and further increase their market share.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides extensive qualitative and quantitative analysis of the current trends and future estimations of the hydroxychloroquine market from 2019 to 2027 to determine the prevailing opportunities.
  • Comprehensive analysis of factors that drive and restrict hydroxychloroquine market growth is provided.
  • The hydroxychloroquine market forecast and estimations are based on factors impacting the market growth, in terms of value.
  • Profiles of leading players operating in the hydroxychloroquine market are provided to understand the global competitive scenario.
  • The report provides extensive qualitative insights on the significant segments and regions exhibiting favorable market share.

KEY MARKET SEGMENTS

By Product type

  • Tablet
  • Active Pharmaceutical Ingredients

By Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Specialty Drug Store
  • Retail Pharmacy

By Disease

  • Malaria
  • Rheumatoid Arthritis
  • Lupus Erythematosus
  • Coronavirus
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA
  • Key Players
  • Cadila Healthcare Ltd
  • Hikma Pharmaceuticals PLC
  • Ipca Laboratories Ltd
  • Mylan N.V
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Taj Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd
  • Zydus Cadila

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Primary research
    • 1.4.2.Secondary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top Player Positioning
    • 3.2.3.Porter's five forces analysis
  • 3.3.Patent Analysis
  • 3.4.Value chain analysis
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Increase in demand for HCQ as potential treatment source amidst pandemic
      • 3.5.1.2.Increase in cases of malaria
    • 3.5.2.Restraint
      • 3.5.2.1.Several side-effects of the medicine
      • 3.5.2.2.Ban from several countries owing to lacking study data
      • 3.5.2.3.Ongoing research and positive results of other drugs for potential cure
    • 3.5.3.Opportunity
      • 3.5.3.1.Repurposing hydroxychloroquine as anti-cancer drug
  • 3.6.Impact of CORONA (COVID 19) outbreak on global hydroxychloroquine market

CHAPTER 4:HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Tablet
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
  • 4.3.Active pharmaceutical ingredient
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region

CHAPTER 5:HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Hospital pharmacy
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
  • 5.3.Retail pharmacy
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by region
  • 5.4.Online pharmacy
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by region
  • 5.5.Specialty drug store
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by region

CHAPTER 6:HYDROXYCHLOROQUINE MARKET, BY DISEASES

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Malaria
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by region
  • 6.3.Rheumatoid arthritis
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by region
  • 6.4.Lupus Erythematosus
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by region
  • 6.5.Coronavirus
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.Market size and forecast, by region
  • 6.6.Others
    • 6.6.1.Key market trends, growth factors, and opportunities
    • 6.6.2.Market size and forecast, by region

CHAPTER 7:HYDROXYCHLOROQUINE MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by product type
    • 7.2.3.Market size and forecast, by distribution channel
    • 7.2.4.Market size and forecast, by disease
    • 7.2.5.Market share analysis, by country
    • 7.2.6.U.S.
      • 7.2.6.1.Market size and forecast, by product type
      • 7.2.6.2.Market size and forecast, by distribution channel
      • 7.2.6.3.Market size and forecast, by disease
    • 7.2.7.Canada
      • 7.2.7.1.Market size and forecast, by product type
      • 7.2.7.2.Market size and forecast, by distribution channel
      • 7.2.7.3.Market size and forecast, by disease
    • 7.2.8.Mexico
      • 7.2.8.1.Market size and forecast, by product type
      • 7.2.8.2.Market size and forecast, by distribution channel
      • 7.2.8.3.Market size and forecast, by disease
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by product type
    • 7.3.3.Market size and forecast, by distribution channel
    • 7.3.4.Market size and forecast, by disease
    • 7.3.5.Market share analysis, by country
    • 7.3.6.Germany
      • 7.3.6.1.Market size and forecast, by product type
      • 7.3.6.2.Market size and forecast, by distribution channel
      • 7.3.6.3.Market size and forecast, by disease
    • 7.3.7.France
      • 7.3.7.1.Market size and forecast, by product type
      • 7.3.7.2.Market size and forecast, by distribution channel
      • 7.3.7.3.Market size and forecast, by disease
    • 7.3.8.UK
      • 7.3.8.1.Market size and forecast, by product type
      • 7.3.8.2.Market size and forecast, by distribution channel
      • 7.3.8.3.Market size and forecast, by disease
    • 7.3.9.Italy
      • 7.3.9.1.Market size and forecast, by product type
      • 7.3.9.2.Market size and forecast, by distribution channel
      • 7.3.9.3.Market size and forecast, by disease
    • 7.3.10.Spain
      • 7.3.10.1.Market size and forecast, by product type
      • 7.3.10.2.Market size and forecast, by distribution channel
      • 7.3.10.3.Market size and forecast, by disease
    • 7.3.11.Rest of Europe
      • 7.3.11.1.Market size and forecast, by product type
      • 7.3.11.2.Market size and forecast, by distribution channel
      • 7.3.11.3.Market size and forecast, by disease
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by product type
    • 7.4.3.Market size and forecast, by distribution channel
    • 7.4.4.Market size and forecast, by disease
    • 7.4.5.Market share analysis, by country
    • 7.4.6.China
      • 7.4.6.1.Market size and forecast, by product type
      • 7.4.6.2.Market size and forecast, by distribution channel
      • 7.4.6.3.Market size and forecast, by disease
    • 7.4.7.Japan
      • 7.4.7.1.Market size and forecast, by product type
      • 7.4.7.2.Market size and forecast, by distribution channel
      • 7.4.7.3.Market size and forecast, by disease
    • 7.4.8.India
      • 7.4.8.1.Market size and forecast, by product type
      • 7.4.8.2.Market size and forecast, by distribution channel
      • 7.4.8.3.Market size and forecast, by disease
    • 7.4.9.Australia
      • 7.4.9.1.Market size and forecast, by product type
      • 7.4.9.2.Market size and forecast, by distribution channel
      • 7.4.9.3.Market size and forecast, by disease
    • 7.4.10.South Korea
      • 7.4.10.1.Market size and forecast, by product type
      • 7.4.10.2.Market size and forecast, by distribution channel
      • 7.4.10.3.Market size and forecast, by disease
    • 7.4.11.Rest of Asia-Pacific
      • 7.4.11.1.Market size and forecast, by product type
      • 7.4.11.2.Market size and forecast, by distribution channel
      • 7.4.11.3.Market size and forecast, by disease
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by product type
    • 7.5.3.Market size and forecast, by distribution channel
    • 7.5.4.Market size and forecast, by disease
    • 7.5.5.Market share analysis, by country
    • 7.5.6.Brazil
      • 7.5.6.1.Market size and forecast, by product type
      • 7.5.6.2.Market size and forecast, by distribution channel
      • 7.5.6.3.Market size and forecast, by disease
    • 7.5.7.Saudi Arabia
      • 7.5.7.1.Market size and forecast, by product type
      • 7.5.7.2.Market size and forecast, by distribution channel
      • 7.5.7.3.Market size and forecast, by disease
    • 7.5.8.South Africa
      • 7.5.8.1.Market size and forecast, by product type
      • 7.5.8.2.Market size and forecast, by distribution channel
      • 7.5.8.3.Market size and forecast, by disease
    • 7.5.9.Rest of LAMEA
      • 7.5.9.1.Market size and forecast, by product type
      • 7.5.9.2.Market size and forecast, by distribution channel
      • 7.5.9.3.Market size and forecast, by disease

CHAPTER 8:COMPANY PROFILES:

  • 8.1.Cadila Healthcare Limited
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Product portfolio
    • 8.1.4.Business performance
  • 8.2.Hikma Pharmaceuticals PLC
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Product portfolio
    • 8.2.4.Business performance
  • 8.3.IPCA Laboratories Ltd.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Product portfolio
    • 8.3.4.Business performance
    • 8.3.5.Key Developmental strategies
  • 8.4.Mylan N.V.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Product portfolio
    • 8.4.4.Business performance
    • 8.4.5.Key Developmental strategies
  • 8.5.Novartis International AG
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.Pfizer Inc.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Product portfolio
    • 8.6.4.Business performance
  • 8.7.Sanofi S.A.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Product portfolio
    • 8.7.4.Business performance
  • 8.8.Taj Pharma Group
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Product portfolio
  • 8.9.Teva Pharmaceutical Industries Ltd.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Product portfolio
    • 8.9.4.Business performance
  • 8.10.Torrent Pharmaceuticals Limited
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Product portfolio
    • 8.10.4.Business performance

LIST OF TABLES

  • TABLE 01.GLOBAL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 02.HYDROXYCHLOROQUINE MARKET FOR TABLET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.HYDROXYCHLOROQUINE MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENT, BY REGION, 2019-2027 ($MILLION)
  • TABLE 04.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 05.HYDROXYCHLOROQUINE MARKET FOR HOSPITAL PHARMACY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 06.HYDROXYCHLOROQUINE MARKET FOR RETAIL PHARMACY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.HYDROXYCHLOROQUINE MARKET FOR ONLINE PHARMACY, BY REGION, 2019-2027 ($MILLION)
  • TABLE 08.HYDROXYCHLOROQUINE MARKET FOR SPECIALTY DRUG STORE, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISEASES, 2019-2027 ($MILLION)
  • TABLE 10.HYDROXYCHLOROQUINE MARKET FOR MALARIA, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.HYDROXYCHLOROQUINE MARKET FOR RHEUMATOID ARTHRITIS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.HYDROXYCHLOROQUINE MARKET FOR LUPUS ERYTHEMATOSUS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 13.HYDROXYCHLOROQUINE MARKET FOR CORONAVIRUS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.HYDROXYCHLOROQUINE MARKET FOR OTHERS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 15.HYDROXYCHLOROQUINE MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 16.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 17.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 18.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 19.NORTH AMERICA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 20.U.S. HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 21.U.S. HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 22.U.S. HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 23.CANADA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 24.CANADA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 25.CANADA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 26.MEXICO HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 27.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 28.MEXICO HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 29.EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 30.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 31.EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 32.EUROPE HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 33.GERMANY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 34.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 35.GERMANY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 36.FRANCE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 37.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 38.FRANCE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 39.UK HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 40.UK HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 41.UK HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 42.ITALY HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 43.ITALY HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 44.ITALY HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 45.SPAIN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 46.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 47.SPAIN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 48.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 49.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 50.REST OF EUROPE HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 51.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 52.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 53.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 54.ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 55.CHINA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 56.CHINA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 57.CHINA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 58.JAPAN HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 59.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 60.JAPAN HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 61.INDIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 62.INDIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 63.INDIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 64.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 65.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 66.AUSTRALIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 67.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 68.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 69.SOUTH KOREA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 70.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 73.LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 74.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 75.LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 76.LAMEA HYDROXYCHLOROQUINE MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 77.BRAZIL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 78.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 79.BRAZIL HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 80.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 81.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 82.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 83.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 84.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 85.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 86.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILLION)
  • TABLE 87.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
  • TABLE 88.REST OF LAMEA HYDROXYCHLOROQUINE MARKET, BY DISEASE, 2019-2027 ($MILLION)
  • TABLE 89.ZYDUS CADILA: COMPANY SNAPSHOT
  • TABLE 90.ZYDUS CADILA: PRODUCT PORTFOLIO
  • TABLE 91.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 92.HIKMA: COMPANY SNAPSHOT
  • TABLE 93.HIKMA: PRODUCT PORTFOLIO
  • TABLE 94.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 95.IPCA: COMPANY SNAPSHOT
  • TABLE 96.IPCA: PRODUCT PORTFOLIO
  • TABLE 97.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 98.IPCA: PRODUCT PORTFOLIO
  • TABLE 99.MYLAN: COMPANY SNAPSHOT
  • TABLE 100.MYLAN: PRODUCT PORTFOLIO
  • TABLE 101.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 102.MYLAN: PRODUCT PORTFOLIO
  • TABLE 103.NOVARTIS: COMPANY SNAPSHOT
  • TABLE 104.NOVARTIS: OPERATING SEGMENTS
  • TABLE 105.NOVARTIS: PRODUCT PORTFOLIO
  • TABLE 106.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 107.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 108.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 109.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 110.SANOFI: COMPANY SNAPSHOT
  • TABLE 111.SANOFI: PRODUCT PORTFOLIO
  • TABLE 112.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 113.TAJ: COMPANY SNAPSHOT
  • TABLE 114.TAJ: PRODUCT PORTFOLIO
  • TABLE 115.TEVA: COMPANY SNAPSHOT
  • TABLE 116.TEVA: PRODUCT PORTFOLIO
  • TABLE 117.OVERALL FINANCIAL STATUS ($MILLION)
  • TABLE 118.TORRENT: COMPANY SNAPSHOT
  • TABLE 119.TORRENT: PRODUCT PORTFOLIO
  • TABLE 120.OVERALL FINANCIAL STATUS ($MILLION)

LIST OF FIGURES

  • FIGURE 01.KEY MARKET SEGMENTS
  • FIGURE 02.EXECUTIVE SUMMARY, BY SEGMENT
  • FIGURE 03.EXECUTIVE SUMMARY, BY COUNTRY
  • FIGURE 04.TOP INVESTMENT POCKETS
  • FIGURE 05.TOP PLAYER POSITIONING
  • FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 07.HIGH THREAT OF NEW ENTRANTS
  • FIGURE 08.LOW THREAT OF SUBSTITUTES
  • FIGURE 09.HIGH INTENSITY OF RIVALRY
  • FIGURE 10.HIGH BARGAINING POWER OF BUYERS
  • FIGURE 11.PATENT ANALYSIS FOR HYDROXYCHLOROQUINE
  • FIGURE 12.VALUE CHAIN ANALYSIS FOR HYDROXYCHLOROQUINE MARKET
  • FIGURE 13.HYDROXYCHLOROQUINE MARKET DYNAMICS
  • FIGURE 14.GLOBAL HYDROXYCHLOROQUINE MARKET, BY PRODUCT TYPE, 2019-2027 ($MILILION)
  • FIGURE 15.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR TABLET, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 16.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR ACTIVE PHARMACEUTICAL INGREDIENT, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 17.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILILION)
  • FIGURE 18.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 20.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 21.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR SPECIALTY DRUG STORE, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 22.GLOBAL HYDROXYCHLOROQUINE MARKET, BY DISEASES, 2019-2027 ($MILILION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR MALARIA, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR RHEUMATOID ARTHRITIS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 25.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR LUPUS ERYTHEMATOSUS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 26.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR CORONAVIRUS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 27.COMPARATIVE ANALYSIS OF HYDROXYCHLOROQUINE MARKET FOR OTHERS, BY COUNTRY, 2019 & 2027 ($MILLION)
  • FIGURE 28.U.S. HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 29.CANADA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 30.MEXICO HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 31.GERMANY HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 32.FRANCE HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 33.UK HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 34.ITALY HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 35.SPAIN HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 36.REST OF EUROPE HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 37.CHINA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 38.JAPAN HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 39.INDIA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 40.AUSTRALIA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 41.SOUTH KOREA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 42.REST OF ASIA-PACIFIC HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 43.BRAZIL HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 44.SAUDI ARABIA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 45.SOUTH AFRICA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 46.REST OF LAMEA HYDROXYCHLOROQUINE MARKET REVENUE, 2019-2027 ($MILLION)
  • FIGURE 47.ZYDUS CADILA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 48.ZYDUS CADILA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 49.ZYDUS CADILA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 50.HIKMA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 51.HIKMA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 52.HIKMA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 53.IPCA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 54.IPCA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 55.IPCA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 56.MYLAN: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 57.MYLAN: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 58.MYLAN: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 59.MYLAN: REVENUE SHARE BY COUNTRY OF SUNSIDIARIES, 2019 (%)
  • FIGURE 60.KOBE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 61.NOVARTIS: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 62.NOVARTIS: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 63.NOVARTIS: REVENUE SHARE BY DIVISION, 2019 (%)
  • FIGURE 64.PFIZER INC.: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 65.PFIZER INC.: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 66.PFIZER INC.: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 67.SANOFI: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 68.SANOFI: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 69.SANOFI: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 70.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 71.TEVA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 72.TORRENT: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 73.TORRENT: REVENUE SHARE BY REGION, 2019 (%)